p53 in rheumatoid arthritis: friend or foe? by Müller-Ladner , Ulf & Nishioka, Kusuki
Commentary
p53 in rheumatoid arthritis: friend or foe?
Ulf Müller-Ladner and Kusuki Nishioka*
University of Regensburg, Regensburg, Germany, and *St Marianna University, Kawasaki, Japan
Abstract
The knowledge of transcription factors and proto-oncogenes has influenced the
understanding of cell regulation, cell cycle, amd apoptotic cell death in rheumatoid arthritis
(RA) synovium. In addition, the development of normal synovial fibroblasts into transformed-
appearing aggressive synovial fibroblasts may be triggered by the lack of antiproliferative
factors, such as p53, p53-associated molecules, other tumor suppressors, as well as by
upregulation of anti-apoptotic genes. Therefore, data derived from experiments such as
those performed by Tak and colleagues in this issue of Arthritis Research not only enrich the
intensive discussion addressing the impact of p53 on RA pathophysiology, they also may
facilitate development of novel therapeutic approaches including p53-targeted gene therapy.
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Introduction
In this issue of Arthritis Research Tak et al [1] present
interesting data on the development of apoptosis and
expression of the tumour suppressor gene p53 in adjuvant
arthritis (AA). The intention of that study was to evaluate
the AA model for its potential to test proapoptotic thera-
peutic strategies in RA.
Because those authors showed that expression of both
apoptosis and p53 occurred rather late during the course
of the disease, and as levels of p53 were even higher than
in RA synovial tissue, the question arises as to whether
p53 is the appropriate molecule to target. The tumour sup-
pressor p53, in general, acts by inducing both growth
arrest and apoptosis. On the basis of the results of that
study [1], and of contributions to our current knowledge of
the regulation of apoptosis in RA synovial fibroblasts
[2–4], p53, when overexpressed early, may ameliorate the
course of the disease. Before extrapolating this approach
to human RA, however, the actual and/or potential role of
p53 in the pathophysiology of RA needs to be discussed
and defined. This issue is addressed by the following
three questions.
p53 in cellular metabolism: gearing up or
gearing down?
For more than a decade, p53 has been one of the most thor-
oughly examined genes in molecular tumor biology [5,6],
which is illustrated by 16597 hits when ‘p53’ is entered into
a PubMed search (http://www.ncbi.nlm.nih.gov/PubMed/).
The physiologic ‘tumor suppressor’ function of p53 (ie its
ability to induce apoptosis) is not restricted to a single
pathway. Once it has formed a homotetramer [7], p53 binds
to specific DNA sequences of various genes involved in
control of cellular growth and apoptosis (eg those that
encode p21Waf1, bax, GADD, 14-3-3D, insulin-like growth
factor-binding protein 3, caspases, Fas, the recently demon-
strated KILLER/DR5 [8] and presumably numerous others).Arthritis Research    Vol 2 No 3 Müller-Ladner and Nishioka
Conversely, p53-modulated pathways that lead to cell arrest
and apoptosis can also be activated by other molecules,
such as members of the tumour necrosis factor family. One
example is TRAIL, a molecule that is known to be involved
specifically in the elimination of tumour cells [8,9].
The majority of these mechanisms is activated by damage
to the cell and its genetic information, of which the latter
needs to be stabilized for an extended period of time in
order to secure the homeostasis of the organism. In
general, activation of oncogenes, DNA damage, or expo-
sure to oxidative stress is followed by activation of p53. As
long as p53 is not mutated (a deleterious effect that may
occur during chronic inflammation [10]), activation of p53
results in apoptosis or DNA repair, which means protec-
tion of the organism from development of continuous cel-
lular proliferation and malignant transformation [11,12].
Apart from sole expression or absence of p53, its effect
can also be modulated by cellular factors and infectious
agents. For example, the oncogene MDM2 is critical for
p53 subcellular distribution [13] and can degrade p53
rapidly [14], and human herpesvirus proteins are able to
repress p53 transcriptional activity [15], finally inducing
malignant transformation.
Dysfunction of p53 occurs also when the p53 gene itself
is mutated; this knowledge, which was achieved more
than a decade ago [16], is regarded as one of the basic
scientific keys that facilitates understanding of the devel-
opment of malignancies. The impact of p53 gene muta-
tions is reflected also by the fact that numerous tumours
are based on p53 mutations [17,18] (eg more than 70%
of colorectal cancers bear mutations within the p53 gene,
which has already been targeted by gene therapy
approaches [19]).
The p53 ‘picture’ will soon become even more colourful,
because recent data show that p53 is not a molecule that
stands alone, but is a member of a growing family [20].
Currently the most important members of this family are
p73 and Ket (named also p40, p51, p63 and p73L,
respectively; for review see [21]).
In summary, when p53-dependent mechanisms are
studied for novel therapeutic approaches, both sides of
the p53 coin(s) need to be examined. Gearing up of p53
may induce apoptosis, and may downregulate inflamma-
tion as well as proliferation. On the other hand, gearing
down of p53 may reveal key pathways that are involved in
these mechanisms.
p53 in (rheumatoid) arthritis: what do we
know?
When submitted to PubMed, the combination of p53 with
arthritis elicits only 25 hits, and this number is even lower
when ‘rheumatoid’ is added, resulting in only a few articles
with the majority of the work performed by Firestein and
various collaborators [1,3,10,22–29].
p53 is expressed in RA synovium, and cultured rheuma-
toid synovial fibroblasts probably contribute to this expres-
sion [22]. The idea that p53 may play an important role in
regulation of cellular proliferation in rheumatoid synovium
was supported by experiments that showed that, similar to
in human tumours, transduction of synovial fibroblasts with
papilloma virus E6 protein result in a decrease in p53
activity and increased cell growth [23]. Moreover, when
examined in the severe combined immunodeficiency virus
mouse model for RA [30], E6-transduced synovial fibro-
blasts showed enhanced aggressiveness towards co-
implanted human cartilage [24].
Deducted from tumour biology as outlined above, p53
activity might also be altered when key bases in its gene
sequence are mutated. Mutations at five ‘hotspot’ codons
account for at least 20% of the known mutations [31]. Dif-
ferent research groups, however, have shown that, within
rheumatoid synovium, various mutations apart from those
in the known ‘hot spots’ are present, but are infrequent
when compared with human tumours [25,32]. Of interest,
variability of these mutations within different patient popu-
lations was high [25,32,33], some were dominant nega-
tive [26], and in some synovial fibroblast populations of
RA patients living in the same geographic area they were
even absent [27].
The experiments by Tak et al [1] contribute to this knowl-
edge by demonstrating that expression of p53 in AA is not
a feature that occurs very early during the course of the
disease, but parallels increasing apoptosis in the inflamed
synovial tissue. These data support immunohistological
protein expression studies of p53 that have shown that
expression of p53 in RA was considerably higher in RA
than in osteoarthritis or reactive arthritis synovial speci-
mens [28].
In addition, p53 appears to be involved not only in long-
term disease, but also in early stages of human RA,
because it could be detected shortly after clinical diagno-
sis was possible [28]. Therefore, it may be concluded that
upregulation of p53 in AA is due to similar cell- and DNA-
damaging mechanisms as outlined above, and that
chronic inflammation in RA may also be a key stimulus for
the upregulation of p53 and the number of apoptotic cells
detected in RA synovium [10].
Furthermore, therapeutic approaches currently used for
RA may also interfere with the expression of p53. For
example, overexpression of tumour necrosis factor-a
receptor p55 in RA synovial fibroblasts using adenovirus-
based gene therapy results in upregulation of a MDM2-likehttp://arthritis-research.com/content/2/3/175
p53-binding protein (Fig. 1), which is presumably involved
in regulation and cellular distribution of various members
of the p53 family [13,14,34,35].
p53 in rheumatoid arthritis: what do we not
know?
The various data obtained from the experiments that
attempted to elucidate the role of p53 in (rheumatoid)
arthritis clearly show that its presence must be associated
with the course of the disease, and that there are still
numerous questions to be answered before attributing a
distinct role to p53 in the pathophysiology of RA.
First, we do not know whether p53 protein expression in
rheumatoid synovium means expression of wild-type or
mutated p53 protein, as all antibodies currently available
for immunohistochemistry are not able to detect solely
mutated p53.
Second, it needs to be clarified whether the (few and
inconsistent) mutations in the p53 gene sequence identi-
fied in synovial fibroblasts are sufficient to permit the gen-
eration of the transformed-appearing synovial fibroblasts
located at the sites of invasion into cartilage and bone. In
addition, mechanisms that counteract aberrant p53 are
presumably outweighing the antiapoptotic effects of
mutated  p53, because p53 mutations (unlike in other
tumours) do not result in synovial mesenchymal or lym-
phatic malignancies, for example sarcoma or ‘SALT’
(synovia-associated lymphatic tumour).
Third, it can still be speculated that p53 may not only be
foe, but also a friend that helps to clear the synovium from
aberrant cells induced by various stimuli that are genotoxic
[10] and that inhibits matrix-degrading enzymes [36].
Fourth, it is most likely that p53 is only one of the potential
antiproliferative molecules that are operative (or lacking) in
rheumatoid synovium. This is illustrated by recent experi-
ments that showed that the p53 homologue p73 [29] and
the novel tumour suppressor PTEN [37] could only be
detected in minute amounts in RA synovial fibroblasts.
Finally, it can be speculated that p53 is involved in sus-
ceptibility of a RA patient to antiproliferative medication
(eg in tumours it is known not only that p53 inactivation
results in upregulation of multidrug resistance genes [38],
but also that mutations in the p53 gene lead to acquired
resistance to methotrexate [39]).
Conclusion
Inflammation, altered immune responses and synovial hyper-
plasia are typical features of RA [40]. There is increasing
evidence that T-cell-independent pathways are key players
in the progressive destruction of the affected joints. Knowl-
edge of transcription factors and proto-oncogenes has influ-
enced our understanding of cell regulation, cell cycle and
apoptotic cell death, which can be summarized in an ‘onco-
gene network’ that is operative in RA synovial fibroblasts
[41]. On the other hand, the development of normal synovial
fibroblasts into transformed-appearing synovial fibroblasts
that mediate joint destruction may not only be stimulated
positively by upregulation of proto-oncogenes, but also by
lack of antiproliferative genes such as p53, its relatives and
other distinct tumour suppressors, as well as by upregula-
tion of antiapoptotic genes [42]. Thus, data derived from
experiments such as those performed by Tak et al [1] not
only support our understanding of basic mechanisms that
lead to this disabling disease, but also facilitate develop-
ment of novel therapeutic strategies, including gene therapy
targeting p53-dependent pathways [43,44].
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